3
Announcements
Trials
Browse
Landscape
Phase
Phase 3
1
Phase 1/2
1
Status
Recruiting
1
Active not recruiting
1
Sponsor Class
INDUSTRY
2
Study Type
Interventional
2
Sponsor
Cancer Type
Lymphoid
2
Other hematologic neoplasm
1
Conditions
Multiple Myeloma
29
Lymphoma, Follicular
8
Lymphoma, Large B-Cell, Diffuse
7
Lymphoma
7
Lymphoma, Non-Hodgkin
5
Leukemia, Lymphocytic, Chronic, B-Cell
4
Neoplasms
3
Smoldering Multiple Myeloma
2
Myelodysplastic Syndromes
2
Lymphoma, B-Cell, Marginal Zone
2
Leukemia, Plasma Cell
2
Leukemia, Myelomonocytic, Chronic
2
Burkitt Lymphoma
2
Recurrence
1
Neoplasms, Plasma Cell
1
Lymphoma, Mantle-Cell
1
Lymphoma, B-Cell
1
Leukemia, Hairy Cell
1
Leukemia
1
Hodgkin Disease
1
Hematologic Diseases
1
GATA2 Deficiency
1
Anemia, Refractory, with Excess of Blasts
1
Anemia
1
Interventions
venetoclax
5
Rituximab
5
Cyclophosphamide
4
Whole-Body Irradiation
3
Magnetic Resonance Spectroscopy
3
Cyclosporine
3
zanubrutinib
2
pirtobrutinib
2
fludarabine phosphate
2
fludarabine
2
Specimen Handling
2
Prednisone
2
Mycophenolic Acid
2
Lenalidomide
2
CT-P10
2
Biopsy
2
treosulfan
1
pomalidomide
1
obinutuzumab
1
ibrutinib
1
Vincristine
1
Tacrolimus
1
Stem Cell Transplantation
1
Sirolimus
1
R-CHOP protocol
1
Peripheral Blood Stem Cell Transplantation
1
Oxaliplatin
1
Methotrexate
1
Melphalan
1
Maintenance
1
Date Range
30 days
90 days
1 year
All
Options
Has results
Has announcements
Clinical Trials
2 trials
Recent
Start date
Enrollment
Lymphoma, B-Cell, Marginal Zone
×
Lenalidomide
×
30 days
×
Clear all
NCT04542824
2026-06-02
EPCOREâ„¢ NHL-3
Genmab
Phase 1/2
Active not recruiting
78 enrolled
NCT05100862
2026-05-27
MAHOGANY
BeOne Medicines
Phase 3
Recruiting
780 enrolled